Clinicians also frequently overlook the additive ASCVD risk of elevated lipoprotein(a) [Lp(a)], despite its independent, genetically determined role in atherosclerosis and the growing body of data supporting one-time screening and targeted therapy. New therapies in development, including siRNA and antisense oligonucleotides, further complicate treatment decisions and highlight the need for timely, expert-led education. In this CME Outfitters recorded webcast, expert faculty will propose a curriculum that combats inertia by dispelling persistent myths, clarifying evidence-based strategies, and empowering clinicians to implement current and emerging therapies in everyday practice to improve lipid outcomes and reduce ASCVD-related morbidity and mortality.
In this CME Outfitters chapter series, expert faculty will discuss strategies for identifying disparities when caring for persons of color living with HIV, communicating about HIV risk with patients from diverse backgrounds, and develop long-term, personalized care plans that include rapid initiation of antiretroviral therapies (ARTs) and support for treatment adherence for PLWH.
In this CMEO recorded webcast, expert faculty will present and discuss advances in non-factor therapies for hemophilia, including advancements in laboratory and monitoring practices and how to use shared decision-making (SDM) with patients to design individualized care plans that incorporate non-factor replacement therapies into treatment.
In this CME Outfitters recorded webcast, expert faculty will discuss the role of FcRn in the pathogenesis of gMG, evaluate the safety and efficacy of FcRn antagonists for the treatment of gMG, and provide expert guidance on how to identify patients with gMG who may be appropriate candidates for treatment with FcRn antagonists. Finally, they will model development of optimized and individualized treatment plans for patients with gMG receiving FcRn antagonists, providing learners with key skills to bring back to clinical practice.
In this CME Outfitters recorded symposium, leading experts will explore:
✅ Early, guideline-based diagnosis to improve patient outcomes
✅ The latest efficacy and safety data on current and emerging therapies, including oral treatments
✅ Individualized care strategies that consider patient needs, comorbidities, and barriers to adherence
Stay ahead of the curve with cutting-edge insights to enhance patient care and optimize long-term management of acromegaly.
In this CME Outfitters recorded symposium, faculty will examine the role of pro-inflammatory cytokines in the pathogenesis of IBD, discern differences in IL-23 binding among IL-23p19–targeted therapies, assess the safety and efficacy of IL-23p19–targeted therapies for the treatment of IBD, and explore when to incorporate IL-23p19–targeted therapies into the management of patients with IBD.
